Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells

Biochemical Pharmacology

Volumn 51, Issue 4, 1996, Pages 489-493

  Fritzer, Monika ^a   Szekeres, Thomas ^a   Szüts, Viktoria ^b   Jarayam, Hiremagalur N ^c   Goldenberg, Hans ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

clonogenic cytotoxicity; doxorubicin transferrin conjugate; human epidermoid carcinoma KB cells; multidrug resistance; transferrin receptor sites

Indexed keywords

DOXORUBICIN; DOXORUBICIN TRANSFERRIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL STRAIN KB; CLONOGENIC ASSAY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0030060479     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02225-2     Document Type: Article

References (28)

1. Endicott JA and Ling V, The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
2. Gottesman MM, How cancer cells evade chemotherapy. Cancer Res 53: 747-754, 1993.
3. Barabas K, Sizensky JA and Faulk WP, Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA. J Biol Chem 267: 9437-9442, 1992.
4. Bërczi A, Ruthner M, Szüts V, Fritzer M, Schweinzer E and Goldenberg H, Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis. Eur J Biochem 213: 427-436, 1993.
5. Faulk WP, Hsi BL and Stevens PJ, Transferrin and transferrin receptors in carcinoma of the breast. Lancet II: 390-392, 1980.
6. Yeh C-JG and Faulk WP, Killing of human tumor cells in culture with adriamycin conjugates of human transferrin. Clin Immunol Immunopathol 32: 1-11, 1984.
7. Berczi A, Barabas K, Sizensky JA and Faulk WP, Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL-60 cells. Arch Biochem Biophys 300: 356-363, 1993.
8. Faulk WP, Taylor CG, Yeh C-JG and McIntyre JA, Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients. Mol Biother 2: 57-60, 1990.
9. Akiyama S-I, Fojo A, Hanover JA, Pastan I and Gottesman MM, Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11: 117-126, 1985.
10. Fraker JP and Speck JC Jr, Protein and cell membrane iodinations with a sparingly soluble chloroamide 1,3,4,6-tetrachloro-3a,6a-diphenylglycouril. Biochem Biophys Res Commun 80: 849-857, 1978.
11. Szekeres T, Cho-Chung YS and Weber G, Action of tiazofurin and 8-C1-cAMP in human colon and pancreatic cancer cells. Cancer Biochem Biophys 13: 67-74, 1992.
12. Bradford MM, Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
13. Sato S, Iwaizumi M, Handa K and Tamura Y, Electron spin resonance study on the mode of generation of free radicals of daunomycin, adriamycin and carboquone in NAD(P)H-microsome system. Gann 68: 603-608, 1977.
14. Waring MJ, DNA modification and cancer. Annu Rev Biochem 50: 159-192, 1981.
15. Tritton TR, Cell surface actions of adriamycin. Pharmacol Ther 49: 293-309, 1991.
16. Pastan I and Gottesman MM, Multidrug resistance. Annu Rev Med 42: 277-286, 1991.
17. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H and Lechner K, MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708-712, 1991.
18. Szüts V, Bérczi A, Schweinzer E and Goldenberg H, Binding of doxorubicin-conjugated transferrin to U937 cells. J Recept Res 13: 1041-1054, 1993.
19. Ruthner M, Bérczi A and Goldenberg H, Interaction of a doxorubicin-transferrin conjugate with isolated transferrin receptors. Life Sci 54: 35-40, 1994.
20. Fritzer M, Barabas K, Szüts V, Bérczi A, Szekeres T, Faulk WP and Goldenberg H, Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells. Int J Cancer 52: 619-623, 1992.
21. Tarasiuk J and Garnier-Suillerot A, Kinetic parameters for the uptake of anthracycline by drug-resistant and drug-sensitive K562 cells. Eur J Biochem 204: 693-698, 1992.
22. Li M and Center MS, Regulation of ribosomal protein S25 in HL-60 cells isolated for resistance to adriamycin. FEBS Lett 298: 142-144, 1992.
23. Zwelling LA, Bales E, Altschuler E and Mayes J, Circumvention of resistance by doxorubicin, but not by idarubicin, in a human leukemia cell line containing an intercalator-resistant form of topoisomerase II: Evidence for a non-topoisomerase II-mediated mechanism of doxorubicin cytotoxicity. Biochem Pharmacol 45: 516-520, 1993.
24. Dillman RO, Johnson RE, Shawler DL and Koziol JA, Superiority of an acid-labile daunorubicin-monoclonal antibody conjugate compared to free drug. Cancer Res 48: 6097-6102, 1988.
25. Braslawsky GR, Kadow K, Knipe J, McGoff K, Edson M, Kaneko T and Greenfield RS, Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular hydrolysis for antitumor activity. Cancer Immunol Immunother 33: 367-374, 1991.
26. Shih LB, Goldenberg DM, Xuan H, Lu H, Sharkey RM and Hall TC, Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier. Cancer Res 51: 4192-4198, 1991.
27. Drew L, Groome N, Hallam TJ, Warr JR and Rumsby MG, Changes in protein kinase C subspecies protein expression and activity in a series of multidrug-resistant human KB carcinoma cell lines. Oncol Res 6: 429-438, 1994.
28. Bellamy WT and Dalton WS, Multidrug resistance in the laboratory and clinic. In: Advances in Clinical Chemistry (Ed. Spiegel HE), Vol. 31, pp. 1-61. Academic Press, San Diego, 1994.